GXI Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Gerresheimer (ETR: GXI)
›
Gerresheimer (ETR: GXI) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 13,301 employees.
The shares were at 33.00 EUR on 19 November 2026, up 35.6% over 52 weeks. Its 52-week range is 14.83 EUR to 34.20 EUR: the price is 3.5% below the high and 122.5% above the low.
Its market capitalisation is 1.14B EUR.
Gerresheimer reports return on equity of -29.6%, an operating margin of 1.6% and revenue down 0.8% year over year.
Its debt exceeds its cash by 2.16B EUR, a debt-to-equity ratio of 2.01. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock; their mean price target of 27.54 EUR is 16.5% below the current price. The next earnings report is expected on 25 November 2026.